KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Co-Diagnostics (CODX) Inventory (2017 - 2025)

Historic Inventory for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to $1.1 million.

  • Co-Diagnostics' Inventory fell 1390.66% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 1390.66%. This contributed to the annual value of $1.1 million for FY2024, which is 3556.15% down from last year.
  • According to the latest figures from Q3 2025, Co-Diagnostics' Inventory is $1.1 million, which was down 1390.66% from $1.1 million recorded in Q2 2025.
  • Co-Diagnostics' Inventory's 5-year high stood at $6.2 million during Q1 2021, with a 5-year trough of $1.1 million in Q4 2024.
  • Over the past 5 years, Co-Diagnostics' median Inventory value was $3.3 million (recorded in 2021), while the average stood at $3.2 million.
  • Within the past 5 years, the most significant YoY rise in Co-Diagnostics' Inventory was 80333.87% (2021), while the steepest drop was 7493.28% (2021).
  • Over the past 5 years, Co-Diagnostics' Inventory (Quarter) stood at $2.0 million in 2021, then skyrocketed by 164.97% to $5.3 million in 2022, then tumbled by 68.65% to $1.7 million in 2023, then plummeted by 35.56% to $1.1 million in 2024, then increased by 1.61% to $1.1 million in 2025.
  • Its Inventory stands at $1.1 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.1 million for Q1 2025.